 |
市場調查報告書
商品編碼
1796142
急性缺血性腦中風治療市場規模、佔有率、成長分析（按診斷、藥物類別和地區）- 產業預測（2025 年至 2032 年）Acute Ischemic Stroke Therapeutics Market Size, Share, and Growth Analysis, By Diagnosis (CT, MRI), By Drug Class (Tissue Plasminogen Activator, Anticoagulant), By Region - Industry Forecast 2025-2032 |
||||||
預計 2023 年全球急性缺血性腦中風治療市場價值將達到 84 億美元，並從 2024 年的 91.3 億美元成長到 2032 年的 178 億美元，預測期內（2025-2032 年）的複合年成長率為 8.7%。
由於腦血管疾病的盛行率不斷上升，以及先進溶栓藥物和機械血栓切除術的日益普及，全球急性缺血性腦中風治療市場正在經歷顯著成長。推動這一市場發展的關鍵因素是高血壓、糖尿病和心房顫動等生活方式相關風險因素的發病率不斷上升，這些因素會增加中風風險，並加劇了及時干預的需求。然而，高昂的治療費用和不足的診斷基礎設施（尤其是在醫療資源匱乏的地區）阻礙了中風的可及性，並且治療窗口狹窄。北美憑藉其強大的認知度、健全的醫療保健系統和優惠的報銷政策，佔據了市場主導地位。同時，對卒中治療和人工智慧診斷的持續投資預計將進一步推動該領域的成長。
目錄
介紹
- 調查目標
- 調查範圍
- 定義
調查方法
- 資訊收集
- 二次資料和一次資料方法
- 市場規模預測
- 市場假設與約束
執行摘要
- 全球市場展望
- 供需趨勢分析
- 細分機會分析
市場動態與展望
- 市場概覽
- 市場規模
- 市場動態
- 促進因素和機會
- 限制與挑戰
- 波特的分析
關鍵市場考察
- 關鍵成功因素
- 競爭程度
- 關鍵投資機會
- 市場生態系統
- 市場吸引力指數（2024年）
- PESTEL分析
- 總體經濟指標
- 價值鏈分析
- 定價分析
- 案例研究
- 顧客購買行為分析
急性缺血性腦中風治療市場規模（按診斷和複合年成長率）（2025-2032）
- 市場概覽
- CT
- MRI
- 頸動脈超音波
- 腦血管血管造影術
急性缺血性腦中風治療市場規模（依藥物類別及複合年成長率）（2025-2032）
- 市場概覽
- 組織胞漿素原原活化劑
- 抗凝血劑
- 抗血小板藥物
- 抗高血壓藥物
急性缺血性腦中風治療市場規模（按地區）及複合年成長率（2025-2032）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲地區
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區
競爭資訊
- 前五大公司對比
- 主要企業市場定位（2024年）
- 主要市場參與者所採取的策略
- 近期市場趨勢
- 公司市場佔有率分析（2024年）
- 主要企業簡介
- 公司詳情
- 產品系列分析
- 按部門分類的公司佔有率分析
- 收益同比對比（2022-2024 年）
主要企業簡介
- Amgen Inc.（United States）
- Pfizer Inc.（United States）
- Sanofi SA（France）
- Novartis International AG（Switzerland）
- Johnson & Johnson（United States）
- Merck & Co., Inc.（United States）
- GlaxoSmithKline plc（United Kingdom）
- AbbVie Inc.（United States）
- Bayer AG（Germany）
- Bristol Myers Squibb（United States）
- AstraZeneca plc（United Kingdom）
- Eli Lilly and Company（United States）
- Takeda Pharmaceutical Company Limited（Japan）
結論和建議
Global Acute Ischemic Stroke Therapeutics Market size was valued at USD 8.4 billion in 2023 and is poised to grow from USD 9.13 billion in 2024 to USD 17.8 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).
The global market for acute ischemic stroke therapeutics is witnessing significant growth, driven by the increasing prevalence of cerebrovascular diseases and the heightened adoption of advanced thrombolytics and mechanical thrombectomy techniques. A major factor fueling this market is the rising incidence of lifestyle-related risk factors such as hypertension, diabetes, and atrial fibrillation, which elevate stroke risk and heighten the necessity for timely interventions. However, challenges persist due to the narrow therapeutic window that limits treatment eligibility, especially in underserved areas, alongside high treatment costs and inadequate diagnostic infrastructure that hinder accessibility. North America dominates the market, supported by strong awareness, robust healthcare systems, and favorable reimbursement practices, while ongoing investments in stroke care and AI diagnostics promise to further propel growth in this sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Ischemic Stroke Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Acute Ischemic Stroke Therapeutics Market Segments Analysis
Global Acute Ischemic Stroke Therapeutics Market is segmented by Diagnosis, Drug Class and region. Based on Diagnosis, the market is segmented into CT, MRI, Carotid Ultrasound and Cerebral Angiography. Based on Drug Class, the market is segmented into Tissue Plasminogen Activator, Anticoagulant, Antiplatelet and Antihypertensive. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Acute Ischemic Stroke Therapeutics Market
The global acute ischemic stroke therapeutics market is significantly influenced by the rising prevalence of stroke, especially within aging demographics. As strokes represent a leading cause of disability and mortality worldwide, the demand for effective treatments has surged. The increasing life expectancy across various populations has heightened the vulnerability to strokes, resulting in a greater need for advanced therapeutics such as thrombolytics, neuroprotective agents, and mechanical thrombectomy techniques. This growing awareness and need for timely and effective intervention in stroke management continue to propel the development and availability of innovative therapeutic solutions in the market.
Restraints in the Global Acute Ischemic Stroke Therapeutics Market
A significant challenge in addressing ischemic stroke lies in the limited treatment window, usually within a few hours for effective thrombolysis. Delays in recognizing symptoms and reaching medical facilities often result in missed chances for treatment. This issue is further compounded in many low- and middle-income areas, where limited access to advanced imaging technologies and a shortage of trained stroke specialists can lead to delays in diagnosis and intervention. Such barriers ultimately restrict the availability and implementation of therapeutic options, hindering the overall management of acute ischemic stroke in affected populations.
Market Trends of the Global Acute Ischemic Stroke Therapeutics Market
The Global Acute Ischemic Stroke Therapeutics market is witnessing a transformative trend driven by the integration of personalized medicine and Artificial Intelligence (AI). By leveraging AI to accurately assess clot locations, predict treatment responses, and inform therapeutic decisions, healthcare providers are enhancing the efficacy of acute stroke interventions. Coupled with advancements in genomics and biomarkers, this trend is fostering more targeted treatment approaches, resulting in optimized patient outcomes. Hospitals that implement AI-assisted stroke triage systems are demonstrating significant improvements in crucial metrics, such as reduced door-to-needle times, which is further propelling interest and investment in innovative stroke care solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Customer Buying Behavior Analysis
Global Acute Ischemic Stroke Therapeutics Market Size by Diagnosis & CAGR (2025-2032)
- Market Overview
- CT
- MRI
- Carotid Ultrasound
- Cerebral Angiography
Global Acute Ischemic Stroke Therapeutics Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
Global Acute Ischemic Stroke Therapeutics Market Size & CAGR (2025-2032)
- North America (Diagnosis, Drug Class)
- US
- Canada
- Europe (Diagnosis, Drug Class)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Diagnosis, Drug Class)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Diagnosis, Drug Class)
- Brazil
- Rest of Latin America
- Middle East & Africa (Diagnosis, Drug Class)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis International AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
